JP2015509110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509110A5 JP2015509110A5 JP2014555351A JP2014555351A JP2015509110A5 JP 2015509110 A5 JP2015509110 A5 JP 2015509110A5 JP 2014555351 A JP2014555351 A JP 2014555351A JP 2014555351 A JP2014555351 A JP 2014555351A JP 2015509110 A5 JP2015509110 A5 JP 2015509110A5
- Authority
- JP
- Japan
- Prior art keywords
- tautomer
- compound
- pharmaceutically acceptable
- alkyl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(*)(C(**1C(*)=C(*)C(*)=C(*)C11)N1C1CCCCCC1)N* Chemical compound *C(*)(C(**1C(*)=C(*)C(*)=C(*)C11)N1C1CCCCCC1)N* 0.000 description 7
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594460P | 2012-02-03 | 2012-02-03 | |
| US61/594,460 | 2012-02-03 | ||
| PCT/IB2013/050555 WO2013114250A1 (en) | 2012-02-03 | 2013-01-22 | Benziimidazole and imidazopyridine derivatives as sodium channel modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509110A JP2015509110A (ja) | 2015-03-26 |
| JP2015509110A5 true JP2015509110A5 (cg-RX-API-DMAC7.html) | 2016-02-12 |
| JP6002785B2 JP6002785B2 (ja) | 2016-10-05 |
Family
ID=47846092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555351A Expired - Fee Related JP6002785B2 (ja) | 2012-02-03 | 2013-01-22 | ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8927587B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2809655B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6002785B2 (cg-RX-API-DMAC7.html) |
| AR (1) | AR089865A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2861439C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2548228T3 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201341370A (cg-RX-API-DMAC7.html) |
| UY (1) | UY34602A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013114250A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014134306A1 (en) | 2013-03-01 | 2014-09-04 | Zalicus Pharmaceuticals, Ltd. | Heterocyclic inhibitors of the sodium channel |
| ES2986650T3 (es) | 2013-12-13 | 2024-11-12 | Vertex Pharma | Proceso y productos intermedios para preparar profármacos de amidas de piridona útiles como moduladores de los canales de sodio |
| WO2015127549A1 (en) * | 2014-02-27 | 2015-09-03 | Hassan Pajouhesh | Heterocyclic inhibitors of the sodium channel |
| JP2017516803A (ja) | 2014-05-30 | 2017-06-22 | ファイザー・インク | ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド |
| WO2016009303A1 (en) | 2014-07-17 | 2016-01-21 | Pfizer Inc. | Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| PT3348547T (pt) * | 2015-09-11 | 2020-10-12 | Sumitomo Dainippon Pharma Co Ltd | Derivados de benzimidazole como inibidores de nav 1.7 (canal de sódio, controlado por tensão, tipo ix, subunidade alfa (scn9a)) para o tratamento de dor, disúria e esclerose múltipla |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| ES2927712T3 (es) | 2017-05-16 | 2022-11-10 | Vertex Pharma | Amidas deuteradas de piridona y profármacos de las mismas como moduladores de canales de sodio |
| JPWO2018212162A1 (ja) * | 2017-05-17 | 2020-03-19 | 株式会社トクヤマ | ジアミノベンゼン化合物の製造方法 |
| ES3008911T3 (en) | 2017-07-11 | 2025-03-25 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| ES2963417T3 (es) * | 2018-01-15 | 2024-03-27 | UCB Biopharma SRL | Derivados de imidazol condensados como moduladores de IL-17 |
| TW202002971A (zh) | 2018-02-12 | 2020-01-16 | 美商維泰克斯製藥公司 | 治療疼痛的方法 |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| US12441703B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| PT4069691T (pt) | 2019-12-06 | 2024-12-18 | Vertex Pharma | Tetrahidrofuranos substituídos como moduladores dos canais de sódio |
| US20230167121A1 (en) * | 2020-04-14 | 2023-06-01 | The Trustees Of The University Of Pennsylvania | Substituted {1,2,4,} triazolo{1,5-a} pyrimidine compounds and use in stabilizing microtubules |
| WO2022108849A1 (en) * | 2020-11-17 | 2022-05-27 | Arisan Therapeutics Inc. | Heterocyclic compounds as therapeutic agents |
| AU2022286438A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| WO2022256702A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| EP4346818B1 (en) | 2021-06-04 | 2025-12-03 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| CN117858875A (zh) | 2021-06-04 | 2024-04-09 | 沃泰克斯药物股份有限公司 | 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂 |
| CA3221938A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| GEAP202416430A (en) | 2021-06-04 | 2024-03-25 | Vertex Pharma | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| CN114249654B (zh) * | 2021-12-30 | 2023-11-14 | 江苏广域化学有限公司 | 烷基苯胺类化合物的制备方法 |
| KR20240134944A (ko) | 2022-01-18 | 2024-09-10 | 쳉두 캉홍 파마슈티칼 코., 엘티디. | 방향족 융합 고리 nav1.8 억제제 및 이의 용도 |
| CN114288289A (zh) * | 2022-02-17 | 2022-04-08 | 昆山彭济凯丰生物科技有限公司 | 具有镇痛和/或止痒功能的药物组合物及其应用 |
| WO2023205778A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3257285A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| JP2025513454A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| CN119677737A (zh) | 2022-04-22 | 2025-03-21 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的杂芳基化合物 |
| JP2025516005A (ja) | 2022-04-25 | 2025-05-23 | サイトワン セラピューティクス インコーポレイテッド | 疼痛の処置のためのnav1.8の二環式複素環アミド阻害剤 |
| IL321269A (en) | 2022-12-06 | 2025-08-01 | Vertex Pharma | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| CN116621789A (zh) * | 2023-05-31 | 2023-08-22 | 上海吉奉生物科技有限公司 | 一种(4s)-3-[2-[[芴甲氧羰基]氨基]乙酰基]-2,2-二甲基-4-恶唑烷羧酸的合成方法 |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| TW202523313A (zh) | 2023-10-23 | 2025-06-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025160286A1 (en) | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8604566D0 (sv) * | 1986-10-27 | 1986-10-27 | Haessle Ab | Novel compunds |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| CA2425185A1 (en) * | 2000-10-06 | 2002-04-11 | Stephane De Lombaert | Benzimidazole and indole derivatives as crf receptor modulators |
| US7022714B2 (en) * | 2002-07-31 | 2006-04-04 | Euro-Celtique S.A. | Aryl substituted benzimidazoles and their use as sodium channel blockers |
| JP4800216B2 (ja) * | 2003-10-24 | 2011-10-26 | エグゼリクシス, インコーポレイテッド | p70S6キナーゼモジュレーターおよび使用方法 |
| WO2005113580A1 (en) | 2004-05-21 | 2005-12-01 | Pfizer Inc. | Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| AU2007233179A1 (en) * | 2006-03-31 | 2007-10-11 | Astrazeneca Ab | Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators |
| BRPI0717596B8 (pt) | 2006-10-18 | 2021-05-25 | Pfizer Prod Inc | compostos de éter biarílico uréia, seu uso e composição farmacêutica que os compreende |
| US20080207683A1 (en) * | 2007-02-15 | 2008-08-28 | Darin Allen | Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| ATE461177T1 (de) | 2007-03-23 | 2010-04-15 | Icagen Inc | Ionenkanal-hemmer |
| MX2009011816A (es) | 2007-05-03 | 2009-11-19 | Pfizer Ltd | Derivados de piridina. |
| CA2685952C (en) | 2007-05-03 | 2012-03-13 | Pfizer Limited | N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain |
| EP2173743A2 (en) | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Sodium channel inhibitors |
| EP2234486A4 (en) * | 2007-12-19 | 2011-09-14 | Scripps Research Inst | BENZIMIDAZOLES AND ANALOGS AS INHIBITORS OF RHO-KINASE |
| EP2072516A1 (en) * | 2007-12-21 | 2009-06-24 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists |
| US8628695B2 (en) | 2008-04-18 | 2014-01-14 | E I Du Pont De Nemours And Company | Surface-modified ruthenium oxide conductive material, lead-free glass(es), thick film resistor paste(s), and devices made therefrom |
| TW201028142A (en) * | 2008-10-30 | 2010-08-01 | Biogen Idec Inc | Heterobicyclic sphingosine 1-phosphate analogs |
| JP5667934B2 (ja) * | 2010-06-28 | 2015-02-12 | 大日本住友製薬株式会社 | 新規2環性複素環化合物からなる医薬 |
| EP2681200A4 (en) * | 2011-03-03 | 2015-05-27 | Zalicus Pharmaceuticals Ltd | INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL |
-
2013
- 2013-01-22 JP JP2014555351A patent/JP6002785B2/ja not_active Expired - Fee Related
- 2013-01-22 ES ES13708908.2T patent/ES2548228T3/es active Active
- 2013-01-22 WO PCT/IB2013/050555 patent/WO2013114250A1/en not_active Ceased
- 2013-01-22 EP EP13708908.2A patent/EP2809655B1/en not_active Not-in-force
- 2013-01-22 CA CA2861439A patent/CA2861439C/en not_active Expired - Fee Related
- 2013-01-29 US US13/752,571 patent/US8927587B2/en not_active Expired - Fee Related
- 2013-01-30 TW TW102103504A patent/TW201341370A/zh unknown
- 2013-01-31 UY UY0001034602A patent/UY34602A/es not_active Application Discontinuation
- 2013-02-01 AR ARP130100299A patent/AR089865A1/es unknown